Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to find how much Mesa Laboratories earns from its Sterilization & Disinfection Control line, or when executives last bought shares? Mesa’s multi-division model makes the typical 10-K a dense, 200-page challenge. Stock Titan turns those complex SEC filings into clear insights in seconds.
Our platform ingests every Mesa Laboratories SEC filing the moment it hits EDGAR and delivers:
- AI-powered summaries that translate accounting notes, segment revenue, and acquisition details into plain language
- Real-time Mesa Laboratories Form 4 insider transactions with alerts for executive stock moves
- Side-by-side comparisons of each Mesa Laboratories quarterly earnings report 10-Q filing so you can spot trends in calibration and genomics sales
- One-click access to 8-K material events, proxy statements on executive compensation, and every amendment in between
Whether you search for “Mesa Laboratories annual report 10-K simplified” or “Mesa Laboratories insider trading Form 4 transactions,” Stock Titan already has the answers. Our AI tags key metrics—gross margin on biological indicators, R&D outlays for biopharma systems, or guidance updates tucked inside an 8-K—so you spend minutes, not hours, extracting what matters.
Monitor executive stock transactions, understand FDA-related disclosures, and compare segment performance across Sterilization, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions—all in one place. Navigate Mesa Laboratories’ disclosures with confidence; Stock Titan makes understanding MLAB’s SEC documents simple.
Mesa Laboratories (MLAB) filed its FY-26 Q1 10-Q for the quarter ended 30-Jun-2025. Net sales rose 2.4% YoY to $59.5 m, while gross margin slipped 200 bp to 62.0% as higher input and labor costs outweighed price and mix. Operating income fell 45% to $3.1 m, but a $6.1 m FX gain drove net income up 40% to $4.7 m, or diluted EPS of $0.85 (vs $0.62).
- Segment trends: Sterilization & Disinfection Control (+10.7% rev, 71.5% GM) offset declines in Biopharma Development (-4.3% rev, GM -11.4 ppt) and Clinical Genomics (-9.7% rev). Calibration Solutions grew 4.7% but margin contracted 4.4 ppt.
- Geography: U.S. sales +2.9% to $27.6 m; China -17% to $5.4 m; other regions +6.9%.
- Cash & debt: Cash fell to $21.3 m (-$6.0 m Q-to-Q) as operating cash flow shrank to $1.9 m (vs $10.7 m). Convertible notes of $97.5 m mature Aug-2025 and are now classified current; revolver balance rose to $14 m. Total leverage 1.8× EBITDA remains within covenants.
- Balance sheet: Inventories up 10.8% to $28.1 m; goodwill lifted by $6.3 m FX. Share count 5.50 m; dividend maintained at $0.16/sh (-$0.9 m cash).
- Guidance/risks: No formal outlook, but management cites tariff pressure, higher refinancing rates on revolver once notes are repaid, and segment-specific demand softness, particularly in China and BPD.
Overall, results show modest top-line expansion driven by SDC, but core profitability and cash generation weakened, and near-term refinancing risk rises as the convertible notes approach maturity.
On August 5, 2025, Mesa Laboratories, Inc. (Ticker: MLAB) filed a Form 8-K reporting that it issued a press release relating to its results for the three months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the Form 8-K.
The Form 8-K states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act and shall not be incorporated by reference into registration statements under the Securities Act. The filing also lists Exhibit 104 (Cover Page Interactive Data File). The report is signed by Gary M. Owens, President and Chief Executive Officer, dated August 5, 2025, and includes the registrant address and Nasdaq listing (symbol MLAB).
Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys reported multiple transactions on June 21, 2025. The transactions involved the vesting of 1,036 Restricted Stock Units (RSUs) and subsequent sale of 454 shares for tax withholding purposes at $95.82 per share. Following these transactions, Sakys directly owns 15,044 shares and indirectly holds 100 shares as custodian for his children.
Mesa Laboratories (NASDAQ:MLAB) reported insider trading activity through a Form 4 filing for SVP Operations Brian David Archbold. The transactions occurred on June 21, 2025, involving restricted stock units (RSUs). Archbold acquired 844 shares at $95.82 per share through RSU conversion and subsequently disposed of 385 shares at the same price, likely for tax withholding purposes. Following these transactions, Archbold holds 2,407 shares directly.
Form 4 filing – Mesa Laboratories Inc. (MLAB)
President & CEO Gary M. Owens reported two transactions dated 06/21/2025: (1) the conversion of 3,301 Restricted Stock Units (Code “M”) into common stock at a referenced price of $95.82 per share, and (2) the withholding of 1,445 shares for tax purposes (Code “F”) at the same price. Following these transactions, Owens’ direct ownership rose from an implied 50,721 shares to 52,577 shares, a net increase of 1,856 shares. The RSUs originated from a grant that vests one-third annually (2024-2026). No open-market purchases or sales were disclosed; all activity relates to equity compensation.
The filing is routine, indicating continued equity alignment but limited new cash investment by the insider.
Mesa Laboratories Inc. (MLAB) – Form 4 insider transaction dated 06/18/2025
Senior Vice-President of Operations Brian D. Archbold reported the automatic conversion of 2,556 restricted stock units (RSUs) into common shares (Transaction Code M) at a reference price of $92.99 per share. To cover tax obligations, he simultaneously disposed of 1,166 shares via a tax-withholding transaction (Code F) at the same price.
Post-transaction direct holdings changed as follows:
- Common stock: 1,948 shares now held directly (down from 3,114 immediately after the RSU conversion).
- Unvested/remaining RSUs: 4,960 units retained, scheduled to vest one-third on 18 June 2025 and on each of the next two anniversaries.
The activity reflects routine equity compensation vesting rather than an open-market purchase or sale; no cash was exchanged for the share acquisition portion.
Mesa Laboratories, Inc. (MLAB) – Form 4 insider transaction filed 06/20/2025
CFO John Sakys reported activity dated 06/18/2025 involving the exercise and settlement of restricted stock units (RSUs) and related tax withholding.
- RSU exercise (Code M): 2,840 common shares were issued upon vesting of previously granted RSUs. Each RSU converts 1-for-1 into common stock.
- Tax withholding (Code F): 1,243 of the newly issued shares were automatically withheld at a reference price of $92.99 to satisfy tax obligations.
After the transactions, Sakys’ direct beneficial ownership changed from 12,865 shares to 14,462 shares, a net increase of 1,597 shares (≈12.4%).
The RSU award vests in three equal annual installments beginning 06/18/2025, providing future potential share deliveries on the next two anniversary dates.
No derivative positions remain other than 5,511 unvested RSUs outstanding.
Because the share acquisition arose from planned equity compensation rather than open-market buying, the filing signals routine ownership growth rather than an active market purchase, though the net increase modestly aligns the CFO’s incentives with shareholders.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
